✦ LIBER ✦

Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin's lymphoma

✍ Scribed by Janet F. Eary; Kenneth A. Krohn; Oliver W. Press; Lawrence Durack; Irwin D. Bernstein

Book ID: 117688168
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 394 KB
Volume: 24
Category: Article
ISSN: 0969-8051
DOI: 10.1016/s0969-8051(97)00098-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Development of Radioimmunotherapy for th

Development of Radioimmunotherapy for the Treatment of Non-Hodgkin’s Lymphoma

✍ P. Multani 📂 Article 📅 2002 🏛 Carden Jennings Publishing 🌐 English ⚖ 148 KB

Radiation therapy for the treatment of n

Radiation therapy for the treatment of non-Hodgkin's lymphoma in childhood

✍ Steven Carabell; Norman Jaffe; Howard Weinstein; Zebulon B. Vance; Robert Filler 📂 Article 📅 1977 🏛 Elsevier Science 🌐 English ⚖ 165 KB

Chemotherapy followed by consolidation r

Chemotherapy followed by consolidation radiation therapy for the treatment of clinical stage ii aggressive histologic type non-hodgkin's lymphoma

✍ Michael J. O'Connell; David P. Harrington; John D. Earle; Gerhard J. Johnson; Jo 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 509 KB

Sixty-three eligible patients with Ann Arbor clinical Stage I1 or IIE aggressive histologic type non-Hodgkin's lymphomas received combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone (COPAJ) as the primary treatment technique. Moderate-dose radiation therapy (2500 to

Cyclophosphamide, vincristine, adriamyci

Cyclophosphamide, vincristine, adriamycin, and prednisone (CHOP) with and without intermediate dose methotrexate for the treatment of non-Hodgkin's lymphomas of diffuse histology

✍ German A. Gomez; Maurice Barcos; Tin Han; Edward S. Henderson 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 702 KB

Peripheral blood progenitor cell collect

Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin’s Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF

✍ Fernando Callera; Luciana Cavenaghi; Cláudio M.T.P. de Melo 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 251 KB

High dose therapy may have no survival b

High dose therapy may have no survival benefit over CHOEP primary chemotherapy for people with aggressive non-Hodgkin’s lymphoma: Abstracted from: Kaiser U, Uebelacker I, Birkmann U et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. Journal of Clinical Oncology 2002; 20: 4413–19

✍ Axel Glasmacher 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 80 KB